Name of the Test:
Matrix Metalloproteinase- 3 (MMP-3)
MMP-3 has been reported to increase,
- Systemic lupus erythomatosis
- Rheumatoid arthritis , especially predicting erosive disease
Clinical research applications:
Matrix metalloproteinases (MMPs) are a family of Zinc and calcium dependent endopeptidases that degrade extracellular matrix proteins. Human Matrix metalloproteinase-3 (MMP-3, Stromelysin-1), may be expressed in fibroblasts, chondrocytes, osteoblasts, endothelial cells, macrophages and keratinocytes. Inflammatory cytokines such as IL-1, TNF-alpha , PGF and oncology cellular transformation markers promote the biosynthesis of MMP-3. Glucocorticosteroids, retinoic acid and estrogen suppresses MMP-3 biosynthesis. MMP-3 may participate in physiological matrix turnover and pathological destruction of the tissue. Serum level of MMP-3 appear to be an useful marker in the diagnosis of rheumatoid arthritis and also for the evaluation of prognosis of joint destruction and cartilage degradation. Increased MMP-3 in systemic lupus erythomatosis appears to be related to lupus nephritis.
MMP-3 in serum is quantitated using an ELISA (Enzyme linked immunosorbent assay) procedure. It is a two-step sandwich-type immunoassay using two antibodies to MMP-3; monoclonal antibody is the capture antibody and signal polyclonal antibody is conjugated with horse-raddish peroxidase (HRP). High concentration of MMP-3 results in high color reading at 450 nm.
Test Information(Test code # 124 ):
Specimen requirements: 1.0 ml (minimum 0.5 ml) of serum.
Shipping requirements: Ship the samples frozen. Shipping samples at room temperature is not accepted.
Turnaround time: Set up every Monday and reported the same day.
Reference Range: Less than 60 ng/ml of serum.
- Yamanaka H (2002) Usefulness of serum matrix metalloproteinase-3(MMP-3) level in the diagnosis of rheumatoid arthritis. Jap Journal of Clinical Medicine 60:2325-2330.
- Posthumus M et al (1999) Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis.
- Green MJ et al (2003) Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 42: 83-88.